Facilities & Capacity

Horizon doubling down on Irish biomanufacturing with drug substance plant

Horizon Therapeutics will build a second facility in Waterford, Ireland to support its rare disease biologics portfolio. In June 2021, Horizon acquired a 44,000 square-foot drug product manufacturing facility from OPKO health’s EirGen Pharma for $65 million. This first step into building a biomanufacturing network for horizon followed the launch of Tepezza (teprotumumab), a monoclonal antibody for thyroid eye disease, and off the back of growing sales of gout treatment Krystexxa (pegloticase). Having tested the waters, the firm will now…

TCR² lauds positive work culture to overcome staff bottlenecks

T-cell receptor firm TCR² Therapeutics told delegates at Advanced Therapies Europe it is key to embed culture into your employees to attract and retain talent in the life science space. Angela Justice, chief people officer at TCR², told attendees that the key three ways to scale your culture lie in “anchor[ing] your culture through the employee life cycle, focus[ing] on retention, and find[ing] your force multipliers.’ Justice noted that a challenge of anchoring culture typically derives from the values of…

ElevateBio inks deal with Pittsburgh University to accelerate CGTs

ElevateBio will use its development and manufacturing platform, BaseCamp, to support the University of Pittsburgh’s cell and gene therapy (CGT) pipeline. The long-term partnership between ElevateBio and the University of Pittsburgh aims to develop CGTs through the implementation of viral vector and cell therapy process development and manufacturing platform, BaseCamp. BaseCamp is designed for both commercial and clinical cell and gene therapies as well as regenerative medicines.  And according to ElevateBio, the University of Pittsburgh will be fully equipped with…

Cytiva and ForecyteBio partner to advance CGTs

Cytiva claims the installation of its FlexFactory facilities will provide ForecyteBio with access to platforms to manufacture viral vectors and plasmid DNA for the US and Chinese markets. Cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) ForcecyteBio will begin the collaboration at Cytiva’s Fast Trak center located in Shanghai, China. “Cytiva‘s Fast Trak Center will consult on process design and development, GMP production platform development, and talent building and training,” a spokesperson for Cytiva told BioProcess Insider.…

Beyond the peak: Catalent prepped for two-third cut in COVID revenues

Increased cell and gene therapy, drug product, and drug substance demand will offset the considerable decline in COVID-19 revenues in FY 2023, says CDMO Catalent. The contract development and manufacturing organization (CDMO) reported its results this week, with its Biologics division – which represents over 50% of its business – pulling in $667 million in Q4 (up 14% year-on-year) and $2.55 billion for the full fiscal year 2022 (up 34%). Catalent’s Biologics segment includes the development and manufacturing for biologic…

Sonoma Bio leases T cell facility in Seattle

Sonoma Bio has entered into a long-term lease agreement to develop an R&D and manufacturing plant in Seattle, Washington. According to Sonoma Biotherapeutics, the 83,000 square-foot center will be dedicated to research, development, and production of gene-modified regulatory T cell (Treg) therapies for inflammatory and autoimmune diseases at scale for its upcoming clinical trials. “Sonoma Bio is at the forefront of developing Treg therapies to treat autoimmune and inflammatory diseases by restoring balance to the immune system, and we are…

Porton Advanced raises $80m for CGT CDMO Operations

Chinese cell and gene therapy (CGT) CDMO Porton Advanced Solutions has completed an $80 million Series B round to expand its business into new markets. The Suzhou, China-based company has built an integrated contract development and manufacturing organization (CDMO) platform that provides plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy and microbial vectors used for gene therapy. Currently, Porton has a 40,000 square-foot R&D and GMP production facility that has been operating for over two years. It expects a…

ABEC injects $11m in NC single-use plant

The expansion will see ABEC invest $11 million to add 50,000 square feet at its facility located in Wilson, North Carolina. According to ABEC, a bioprocess vendor, the expansion will increase its single-use disposable container (DC) manufacturing capacity within its CSR biomanufacturing solutions business. “CSR (custom single run) is ABEC’s single-use equipment product line used for manufacturing vaccines and pharmaceuticals based on biotechnology. The product line includes single-use bioreactors, fermenters, solutions prep and hold systems, and filtration systems,” a spokesperson…

Merck increases biologics footprint with Ireland expansion

Merck & Co. has begun constructing an additional facility at its Carlow, Ireland site to meet demand for its medicines and vaccines. Merck & Co. (known as MSD outside North America) says that construction of a new facility at its existing site in Carlow, Ireland – about 80km south-west of Dublin – will focus specifically on manufacturing next generation oncology biologics. “The demand for MSD’s range of vaccine and biologics products has continued to grow since 2008 and this new…

Thermo Fisher: $180m MA viral vector plant opens doors

Thermo Fisher adds 300,000 square feet of gene therapy manufacturing capabilities through the opening of the Plainville, Massachusetts plant. In the same week a Thermo Fisher facility capital expenditure came to fruition in its single-use materials business, the life sciences services firm has announced a viral vector plant expansion is complete. The Plainville plant was commissioned in May 2020 at a cost of $180 million and, now open, effectively doubles the firm’s commercial viral vector capacity in supporting increased demand…